Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010–2019
Open Access
- 29 November 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 79 (1), 173-180
- https://doi.org/10.1007/s00228-022-03428-6
Abstract
Purpose This study aimed to describe recent trends in ADHD medication use in pregnancy in Norway and Sweden, including prevalence, individual characteristics, and patterns of use. Methods We studied ADHD medication use (amphetamine, dexamphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine) by year and age in pregnancies from 2010 to 2019 identified from the medical birth registers (gestational age ≥ 22 weeks) linked to prescribed drug registers (Norway, N = 577,116; Sweden, N = 1,118,988). We compared characteristics of those who used any ADHD medication in pregnancy to no use in pregnancy. Discontinuation was defined as no use after first trimester. Results ADHD medication use increased from 2010 to 2019 by 3.0 users per 1000 pregnancies in Norway (from 2.5 to 5.5/1000) and by 6.3 per 1000 in Sweden (from 1.6 to 7.9/1000), mainly driven by methylphenidate and since 2015 by lisdexamfetamine. Medication use has increased among pregnant individuals of all age groups, with higher use among the youngest. Pregnant individuals who used ADHD medication were less likely to be married/cohabiting, more likely be nulliparous and to smoke. They had particularly high use of co-medication with antidepressants, anxiolytics/hypnotics, and opioids: 42% in Norway and 65% in Sweden used at least one additional class of psychotropic medication. Most individuals discontinued ADHD medication in pregnancy (85% Norway, 78% Sweden). Conclusion ADHD medication use during pregnancy increased in Norway and Sweden in the last decade. However, discontinuation rates during pregnancy were high. Those who used ADHD medication had more risk factors for pregnancy complications including low parity, smoking, and other psychotropic drug use.Keywords
Funding Information
- ADHD Research Network of the Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (#51379, #51379, #51379, #51379)
- Norges Forskningsråd (301977, 301977, 301977, 273366, 273366, 301977)
- Norwegian Institute of Public Health
This publication has 29 references indexed in Scilit:
- Increasing use of ADHD medications in pregnancyPharmacoepidemiology and Drug Safety, 2015
- Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancyClinical Epidemiology, 2015
- Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register‐based studyPharmacoepidemiology and Drug Safety, 2014
- Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associationsJournal of Clinical Epidemiology, 2013
- Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelinesCurrent Medical Research and Opinion, 2013
- The Pharmacology and Clinical Outcomes of Amphetamines to Treat ADHDCNS Drugs, 2012
- European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDBMC Psychiatry, 2010
- Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysisThe British Journal of Psychiatry, 2009
- The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey ReplicationAmerican Journal of Psychiatry, 2006
- Birthweight by gestational age in NorwayActa Obstetricia et Gynecologica Scandinavica, 2000